FAQ Library

FAQ Library published on November 13, 2017
In this activity, Dr. Bejar discusses patients with familiar history of MDS or AML and whether genetic testing can identify the mutations that increased their risk of progressing to MDS to begin with.
FAQ Library published on October 31, 2017
Dr. Goldberg discusses when it is appropriate to stop a patient's demethylating agent, taking into consideration age and IPSS-R risk group.
FAQ Library published on September 28, 2017
In this activity, Dr. Bejar will discuss a scenario where a patient with unexplained cytopenias is suspected of having MDS, but has a non-diagnostic bone marrow biopsy and a normal karyotype.
FAQ Library published on August 14, 2017
Dr. Larson discusses the challenges associated with treating secondary MDS, and the therapeutic strategies that have demonstrated efficacy in these patients.
FAQ Library published on July 24, 2017
Dr. Larson discusses new insights into the pathophysiology and epigenetics of therapy-related leukemia, and how this knowledge will translate to improved insights into de novo leukemia and MDS.
FAQ Library published on June 12, 2017
Join Dr. Ellen Ritchie as she explains the clinical implications of molecular testing in MDS, such as chromosomal abnormalities and percentage of blasts in the bone marrow biopsy.
FAQ Library published on May 22, 2017
Dr. Ritchie explains the impact of immunotherapy on hematologic malignancies and what the exciting trials in this area could mean for the future in treating patients with MDS.
FAQ Library published on May 15, 2017
Dr. Ritchie describes determining how to manage therapy and supportive care in patients experiencing grade 1 through 3 lenalidomide-induced rash.
FAQ Library published on April 28, 2017
Dr. Ellen Ritchie will discuss factors to consider when selecting therapy for an older patient with high-risk MDS, such as supportive care and comorbid illnesses.
FAQ Library published on February 15, 2017
Join Dr. Komrokji as he discusses the most practical way to risk-stratify patients with MDS, including the IPSS-R and gene mutations.
Page 1 of 6
Results 1 - 10 of 60

Managing MDS would like to recognize and thank Celgene Corporation for their educational support of ManagingMDS.com

©2017 MediCom Worldwide, Inc. All rights reserved